Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

CompletedOBSERVATIONAL

Enrollment

105

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2014

Conditions

Blood Coagulation DisordersHemophilia A

Interventions

BIOLOGICAL

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Patients under daily life treatment receiving Kogenate according to local drug information.

Trial Locations (2)

Many Locations